Pre-made Tinurilimab benchmark antibody ( Whole mAb, anti-CEACAM6/CD66c therapeutic antibody, Anti-CEAL/NCA Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Tinurilimab biosimilar, Whole mAb, Anti-CEACAM6/CD66c Antibody: Anti-CEAL/NCA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tinurilimab (formerly BAY 1834942) is a humanised monoclonal antibody that selectively blocks the immune checkpoint regulator CEACAM6.
| Products Name (INN Index) | Pre-Made Tinurilimab biosimilar, Whole mAb, Anti-CEACAM6/CD66c Antibody: Anti-CEAL/NCA therapeutic antibody |
|---|---|
| INN Name | Tinurilimab |
| Target | CEACAM6 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Bayer,German Cancer Research Center |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Solid tumours |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CEACAM6 |
| Package |
